Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22979556 | 0.84 | ADORA3 (0.40) | ADORA3ADORA1PDE10AMAPTKDM4E | |
| SCHEMBL29646313 | 0.84 | ADORA3 (0.40) | ADORA3ADORA1PDE10AMAPTKDM4E | |
| SCHEMBL22979102 | 0.84 | ADORA3 (0.50) | ADORA3ADORA1PDE10AMAPTKDM4E | |
| SCHEMBL29646428 | 0.84 | ADORA3 (0.50) | ADORA3ADORA1PDE10AMAPTKDM4E | |
| SCHEMBL22988042 | 0.82 | ADORA3 (0.46) | ADORA3ADORA1PDE10AMAPTKDM4E | |
| SCHEMBL22988045 | 0.80 | ADORA3 (0.51) | ADORA3ADORA1MAPTPOLB | |
| SCHEMBL22987398 | 0.79 | HPGD (0.51) | ADORA3ADORA1MAPTHSD17B10ADORA2A | |
| SCHEMBL29646409 | 0.79 | HPGD (0.51) | ADORA3ADORA1MAPTHSD17B10ADORA2A | |
| SCHEMBL22979023 | 0.77 | ADORA3 (0.69) | ADORA3ADORA1MAPTPOLB | |
| SCHEMBL29646414 | 0.77 | ADORA3 (0.69) | ADORA3ADORA1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885ADORA1 21/4885GRM2 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.